Tourmaline Bio, Inc.
TRMLNASDAQHealthcare
$47.98
+$0.00(+0.00%)
Market Cap$1.2B
P/E Ratio—
52W High$48.27
52W Low$11.56
Tourmaline Bio, Inc. (TRML) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · TRML · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Gross Margin %(computed) | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.07B | $0.03B | $0.02B | $0.00B | $0.02B |
| G&A Expenses | $0.02B | $0.01B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.09B | $0.05B | $0.02B | $0.05B | $0.02B |
| Operating Income | ($0.09B) | ($0.05B) | ($0.02B) | ($0.05B) | ($0.02B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.02B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.07B) | ($0.04B) | ($0.02B) | ($0.05B) | ($0.02B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.07B) | ($0.04B) | ($0.02B) | ($0.00B) | ($0.02B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-2.89 | $-8.87 | $-0.97 | $-0.00 | $-33.97 |
| Wtd Avg Shares | 0.03B | 0.00B | 0.02B | 0.01B | 0.00B |
| EBITDA | ($0.09B) | ($0.04B) | ($0.02B) | ($0.05B) | ($0.02B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Tourmaline Bio, Inc. data
About Tourmaline Bio, Inc. (TRML) Income Statement
Tourmaline Bio, Inc. (TRML) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2024, TRML reported revenue of $0.00B, gross profit of ($0.00B) (gross margin —), and net income of ($0.07B) — a net profit margin of —.
Frequently asked questions
TRML · 4 questionsTourmaline Bio, Inc. (TRML) reported revenue of $0.00B for 2024, down —% year-over-year.
TRML revenueTRML salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08